Discontinued — last reported Q4 '25
Other Non-Current Liabilities
Pfizer Other Non-Current Liabilities decreased by 3.6% to $14.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.8%, from $13.30B to $14.20B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 17.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
Significant changes may reflect shifts in lease accounting, changes in employee benefit plans, or the emergence of long-term legal risks.
Detailed definition
A catch-all category for long-term obligations that do not fall into major classifications like debt or deferred taxes....
Peer comparison
Varies significantly by industry; companies with large physical retail footprints often show higher values here due to long-term leases.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.23B | $9.20B | $9.74B | $10.51B | $11.31B | $12.24B | $13.18B | $13.01B | $13.40B | $14.24B | $16.54B | $15.12B | $16.10B | $15.57B | $14.15B | $13.30B | $13.93B | $13.61B | $14.73B | $14.20B |
| QoQ Change | — | +11.8% | +5.9% | +7.9% | +7.6% | +8.2% | +7.7% | -1.3% | +3.0% | +6.3% | +16.1% | -8.6% | +6.4% | -3.3% | -9.1% | -6.0% | +4.8% | -2.3% | +8.2% | -3.6% |
| YoY Change | — | — | — | — | +37.5% | +33.0% | +35.3% | +23.8% | +18.5% | +16.4% | +25.5% | +16.2% | +20.1% | +9.3% | -14.4% | -12.1% | -13.4% | -12.6% | +4.1% | +6.8% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Pfizer's other non-current liabilities?
- Pfizer (PFE) reported other non-current liabilities of $14.20B in Q1 2026.
- How has Pfizer's other non-current liabilities changed year-over-year?
- Pfizer's other non-current liabilities increased by 6.8% year-over-year, from $13.30B to $14.20B.
- What is the long-term trend for Pfizer's other non-current liabilities?
- Over 5 years (2020 to 2025), Pfizer's other non-current liabilities has grown at a 17.2% compound annual growth rate (CAGR), from $6.67B to $14.73B.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts and obligations that aren't due for at least a year.